AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8066102
Drug: Repeated intracervical
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated intracervical application of PGE2 gel (2 h apart)
Trial: 2713518
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with adriamycin, vincristine and methotrexate (AVM), loco-regional radiotherapy and maintenance chemotherapy with vincristine, cyclophosphamide and 5 fluorouracil (VCF)
Trial: 2713518
Drug: Reinforced protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinforced protocol with five drugs: adriamycin, vincristine, cyclophosphamide, methotrexate, 5 FU (AVCMF)
Trial: 2713518
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with adriamycin, vincristine and methotrexate (AVM)
Trial: 30209576
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at a plasma concentration of 1000 ng/mL
Trial: 30209576
Drug: Propofol 20
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 20 mg as a rescue antiemetic
Trial: 25904602
Drug: DBP concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBP concentration (highest quintile ≥7149.4 nmol/L)
Trial: 25904602
Drug: Serum 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25(OH)D (highest group ≥100 nmol/L)
Trial: 25904602
Drug: Serum 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25(OH)D (lowest group <25 nmol/L)
Trial: 16980806
Drug: Daily infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily infant massage therapy by orphanage staff or volunteers for an average of 53 days
Trial: 14626640
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid and micronutrient combination supplementation (including vitamin B12 and B6)
Trial: 8797135
Drug: Ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5 mg oral dose)
Trial: 8797135
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg oral dose)
Trial: 6241770
Drug: 20 ng
RxNorm normalized name: NG
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ng hepatitis B surface antigen aluminium‐adsorbed vaccine, 3 doses of 40 micrograms over 6 months
Trial: 6241770
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine prior to surgery
Trial: 31190122
Drug: Baseline PTH
RxNorm normalized name: ABX-PTH
DrugBank: ABX-PTH (DB05883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PTH of 0 pg/mL
Trial: 31190122
Drug: Baseline PTH
RxNorm normalized name: ABX-PTH
DrugBank: ABX-PTH (DB05883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PTH of 69 pg/mL
Trial: 31190122
Drug: Baseline PTH
RxNorm normalized name: ABX-PTH
DrugBank: ABX-PTH (DB05883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PTH of 58 pg/mL
Trial: 18514105
Drug: OMS103HP (investigational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMS103HP (investigational drug product containing ketoprofen, amitriptyline, and oxymetazoline)
Trial: 12032039
Drug: Propofol 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.2 mg/kg followed by infusion at a rate of 2 mg.kg(‐1).h(‐1)
Trial: 12032039
Drug: IV midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV midazolam 5 mg
Trial: 9706861
Drug: 25% metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% metronidazole sustained release gel
Trial: 9706861
Drug: 3% tetracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% tetracycline ointment
Trial: 23137
Drug: Local application
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application of aspirin
Trial: 21921285
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy with tamoxifen (20 mg/d for 5 years)
Trial: 21921285
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy with tamoxifen (20 mg/d for 5 years)
Trial: 21921285
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy with tamoxifen
Trial: 21921285
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy with tamoxifen
Trial: 17245184
Drug: I methylene
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I methylene blue (various doses)
Trial: 29992150
Drug: 2% Chamaemelum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Chamaemelum nobile gel
Trial: 27401569
Drug: Dihydroartemisinin-piperaquine (DP)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DP) monthly for 1 year
Trial: 17825129
Drug: Tramadol ER
RxNorm normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol ER (300 mg once daily for patients ≥ 75 years; 300-400 mg once daily for patients < 75 years)
Trial: 17825129
Drug: Tramadol ER
RxNorm normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol ER (open-label treatment after placebo-controlled studies)
Trial: 1941057
Drug: MOPP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP chemotherapy (group A, 105 patients)
Trial: 1941057
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (AC6, 23 patients)
Trial: 1941057
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy at 3-month intervals for 1 year (AC10, 26 patients)
Trial: 1941057
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy (MOPP + radiation)
Trial: 24664227
Drug: 1200 mg/d
RxNorm normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg/d of CoQ10
Trial: 24664227
Drug: 2400 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2400 mg/d of CoQ10
Trial: 21849198
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml polidocanol sclerotherapy (30 mg/ml)
Trial: 21849198
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml polidocanol sclerotherapy (30 mg/ml)
Trial: 21849198
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (1 to 4 treatments)
Trial: 21849198
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml polidocanol sclerotherapy for larger hydroceles/spermatoceles
Trial: 21849198
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml polidocanol sclerotherapy for larger hydroceles/spermatoceles
Trial: 19463396
Drug: Guideline-recommended medications
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guideline-recommended medications at 1 year (including aspirin, clopidogrel, ACE inhibitors, and statins)
Trial: 17462482
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of interstitial cystitis (IC) in males
Trial: 17462482
Drug: Diagnosis and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosis and treatment of chronic nonbacterial prostatitis (CP)
Trial: 9264419
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg twice daily
Trial: 29957715
Drug: Intervention Phase
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention Phase I (focused education program and implementation of treatment bundle)
Trial: 29957715
Drug: Intervention Phase
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention Phase II (provision of resources to implement treatment bundle)
Trial: 26431823
Drug: Low-dose rAAV.sFLT-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose rAAV.sFLT-1 (1×10^10 vector genomes)
Trial: 26431823
Drug: High-dose rAAV.sFLT-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rAAV.sFLT-1 (1×10^11 vector genomes)
Trial: 26431823
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no gene therapy treatment)
Trial: 14579214
Drug: Intracoronary nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary nicardipine (0.1 mg)
Trial: 7512402
Drug: Intraprostatic spiral
RxNorm normalized name: Trichinella spiralis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraprostatic spiral treatment
Trial: 3279023
Drug: 75 mg/day
RxNorm normalized name: Lyllana 0.075 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/day trimipramine
Trial: 3279023
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day trimipramine
Trial: 30037045
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of mixed spices
Trial: 28301619
Drug: HBP Lotion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBP Lotion, 0.05% applied twice daily for 14 days
Trial: 20731686
Drug: Aprotinin (280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (280 mg load + 70 mg/hL) administered during donor lung perfusion and peri-operatively to recipients
Trial: 20731686
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered during donor lung perfusion and peri-operatively to recipients
Trial: 8828369
Drug: Aprotinin administration
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin administration
Trial: 17003096
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment 1 mg/m2.d
Trial: 9181901
Drug: Urolase fiber
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urolase fiber (Bard) at 60 Watts for 60 seconds, administered to each lobe at 2, 4, 8 and 10 o'clock positions.
Trial: 30685874
Drug: Eltrombopag (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (50 mg daily starting 3 weeks pre-operatively, continued for 1 week after surgical haemostasis)
Trial: 30685874
Drug: IVIG (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (1 to 2 g/kg administered 1 week pre-operatively, with allowance for a second dose within 1 week after surgical haemostasis)
Trial: 15956010
Drug: Prednisolone (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (7.5 mg/d for 2 years)
Trial: 12540786
Drug: Nadolol plus
RxNorm normalized name: Nadolol
DrugBank: Nadolol (DB01203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nadolol plus spironolactone 100 mg/d (N + S)
Trial: 1705938
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (morphine group): hyperbaric 1% tetracaine with epinephrine and a single subarachnoid dose of Duramorph (morphine sulphate), 0.5 mg
Trial: 1705938
Drug: Group III
RxNorm normalized name: Corticosteroids, potent (group III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III (Dilaudid group): hyperbaric 1% tetracaine with epinephrine and a single subarachnoid dose of Dilaudid (hydromorphone hydrochloride), 0.002 mg/kg
Trial: 6220729
Drug: Buprenorphine 0.3
RxNorm normalized name: buprenorphine 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.3 mg and hyoscine 0.4 mg
Trial: 6220729
Drug: Papaveretum 20
RxNorm normalized name: papaveretum 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaveretum 20 mg and hyoscine 0.4 mg
Trial: 6220729
Drug: Buprenorphine 0.3
RxNorm normalized name: buprenorphine 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.3 mg and papaveretum 20 mg
Trial: 26418044
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for APD (control group)
Trial: 25085020
Drug: Fennel (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fennel (30 mg) soft capsule every 4 hours, 3 days before menstruation until the 5th day for 3 months
Trial: 19237093
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 400 mg (b.i.d.), amoxicillin 1 g (b.i.d.), doxycycline 100 mg (b.i.d.)
Trial: 19237093
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 400 mg (b.i.d.), amoxicillin 1 g (b.i.d.), tetracycline 500 mg (q.i.d.)
Trial: 15356061
Drug: Repaglinide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (1 mg)
Trial: 7302369
Drug: Glipizide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide (5 mg)
Trial: 8087788
Drug: Androgen withdrawal,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen withdrawal, androgen blockade, or combination therapy (first-line treatment modalities)
Trial: 2659995
Drug: Silver sulfadiazine
RxNorm normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver sulfadiazine cream containing epidermal growth factor (10 micrograms per milliliter)
Trial: 31290550
Drug: Web-based cessation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based cessation treatment for SM smokers
Trial: 31290550
Drug: Web-based cessation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based cessation treatment for bisexual smokers
Trial: 31228618
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) plus pharmacotherapy
Trial: 26074287
Drug: wound infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wound infiltration with 15 ml of ropivacaine 10%
Trial: 18930987
Drug: Infliximab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (3 mg/kg) administered intravenously at weeks 0, 2, 6, and every 8 weeks thereafter to week 54
Trial: 14568836
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment with topical 20% 5‐aminolevulinic acid for 3 hours or 14 to 18 hours followed by LP PDL irradiation at 595 nm
Trial: 10969448
Drug: Miacalcic (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miacalcic (100 IU dose, intramuscularly)
Trial: 10969448
Drug: Calcinin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcinin (100 IU dose, intramuscularly)
Trial: 2578716
Drug: Oral methoxsalen
RxNorm normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methoxsalen PUVA
Trial: 28645636
Drug: Theobromine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theobromine (500 mg/day)
Trial: 28383633
Drug: Capecitabine (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1250 mg/m2 for patients <70 years; 1000 mg/m2 for patients ≥70 years, twice daily on days 1-14)
Trial: 28383633
Drug: S-1 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (30 mg/m2 orally twice daily on days 1-14)
Trial: 26358345
Drug: Nasal triamcinolone
RxNorm normalized name: triamcinolone Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal triamcinolone acetonide 220 μg once daily for 28 days
Trial: 21884606
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose vitamin A supplementation (VAS)
Trial: 21884606
Drug: Recommended dose
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended dose vitamin A supplementation (VAS)
Trial: 19994681
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine group (oral administration of Diethylstilbestrol tablet)
Trial: 17900050
Drug: ECT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECT treatment (bitemporal ECT 3 times a week)
Trial: 17900050
Drug: Imipramine or
RxNorm normalized name: imipramine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine or desipramine (150-250 mg/day)
Trial: 16395953
Drug: ECT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECT treatment
Trial: 11951995
Drug: New formula
RxNorm normalized name: Correct (New Formula)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formula (<0.1 mg Fe 100 ml(‐1))
Trial: 11951995
Drug: Standard formula
RxNorm normalized name: Standard formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formula (0.5 mg Fe 100 ml(‐1))
Trial: 9849711
Drug: Extra-amniotic balloon
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-amniotic balloon with intracervical PGE2 (0.5 mg x 2)
Trial: 9849711
Drug: Extra-ovular Foley
RxNorm normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-ovular Foley catheter with intrauterine PGF2alpha (1 mg/h x 6)
Trial: 7746297
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg b.i.d. for 4 weeks
Trial: 7746297
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg once-daily for 4 weeks
Trial: 2563963
Drug: Nonenteric coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonenteric coated pancreatic enzyme supplement without ranitidine
Trial: 2563963
Drug: Nonenteric coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonenteric coated pancreatic enzyme supplement with ranitidine
Trial: 2563963
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated pancreatic enzyme supplements
Trial: 30735435
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with pembrolizumab
Trial: 29389742
Drug: Control (discontinue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (discontinue all antihypertensive medications)
Trial: 19907103
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 20 mg/day for 12 months
Trial: 19907103
Drug: Amlodipine besilate
RxNorm normalized name: Amlodipine besilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine besilate 5 mg/day for 12 months
Trial: 9062436
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of questionnaires
Trial: 8383388
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (25 units, intramuscular)
Trial: 22199189
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive pill (OCP)
Trial: 30770758
Drug: L-theanine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine supplementation (150 mg for 6 weeks)
Trial: 12904193
Drug: Clonidine 10-min
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 10-min group (3 microg x kg‐1 of clonidine administered for 10 min immediately after the spinal block)
Trial: 12904193
Drug: Clonidine 60-min
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 60-min group (3 microg x kg‐1 of clonidine administered for 10 min, 50 min after the spinal block)
Trial: 7854171
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 to 40 mg/d)
Trial: 1791391
Drug: Phyllanthus amarus
RxNorm normalized name: Phyllanthus amarus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllanthus amarus 600 mg per day for 30 days
Trial: 1791391
Drug: Phyllanthus amarus
RxNorm normalized name: Phyllanthus amarus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllanthus amarus 1,200 mg per day for 30 days
Trial: 26407698
Drug: 38 %
RxNorm normalized name: dextrose 38 % in water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38 % silver diamine fluoride (SDF) solution